{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:17:17Z","timestamp":1790223437127,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100012440","name":"Berrikuntza + Ikerketa + Osasuna Eusko Fundazioa","doi-asserted-by":"publisher","award":["2016111083"],"award-info":[{"award-number":["2016111083"]}],"id":[{"id":"10.13039\/501100012440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-025-05606-4","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T08:38:48Z","timestamp":1755679128000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Role of prostate health index (PHI) in prostate cancer screening: cost minimization analysis through simulation modelling"],"prefix":"10.1007","volume":"43","author":[{"given":"Leire","family":"Rius Bilbao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urko","family":"Aguirre Larracoechea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Valladares Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Mar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Mar Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Phi Basque Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"key":"5606_CR1","doi-asserted-by":"publisher","unstructured":"James ND, Tannock I, N\u2019Dow J et al (2024) The Lancet Commission on prostate cancer: planning for the surge in cases. Lancet. 403(10437):1683\u20131722. https:\/\/doi.org\/10.1016\/S0140-6736(24)00651-2. Epub 2024 Apr 4. Erratum in: Lancet. 2024;403(10437):1634. PMID: 38583453","DOI":"10.1016\/S0140-6736(24)00651-2"},{"issue":"2","key":"5606_CR2","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","volume":"84","author":"O Bergengren","year":"2023","unstructured":"Bergengren O, Pekala KR, Matsoukas K et al (2023) Update on prostate cancer epidemiology and risk Factors-A systematic review. Eur Urol 84(2):191\u2013206. https:\/\/doi.org\/10.1016\/j.eururo.2023.04.021Epub 2023 May 16. PMID: 37202314","journal-title":"Eur Urol"},{"issue":"6","key":"5606_CR3","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.eururo.2013.12.062","volume":"65","author":"S Loeb","year":"2014","unstructured":"Loeb S, Bjurlin MA, Nicholson J et al (2014) Overdiagnosis and overtreatment of prostate cancer. Eur Urol 65(6):1046\u20131055. https:\/\/doi.org\/10.1016\/j.eururo.2013.12.062","journal-title":"Eur Urol"},{"issue":"1","key":"5606_CR4","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3390\/jpm14010084","volume":"14","author":"K Beyer","year":"2024","unstructured":"Beyer K, Leenen R, Venderbos LDF et al (2024) Health policy for prostate cancer early detection in the European union and the impact of opportunistic screening: PRAISE-U consortium. J Pers Med 14(1):84. https:\/\/doi.org\/10.3390\/jpm14010084PMID: 38248785; PMCID: PMC10819943","journal-title":"J Pers Med"},{"issue":"3","key":"5606_CR5","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.eururo.2014.12.006","volume":"68","author":"R Arnsrud Godtman","year":"2015","unstructured":"Arnsrud Godtman R, Holmberg E, Lilja H, Stranne J, Hugosson J (2015) Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the G\u00f6teborg randomized population-based prostate cancer screening trial. Eur Urol 68(3):354\u2013360 Epub 2014 Dec 31. PMID: 25556937","journal-title":"Eur Urol"},{"issue":"1","key":"5606_CR6","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","volume":"76","author":"J Hugosson","year":"2019","unstructured":"Hugosson J, Roobol MJ, M\u00e5nsson M et al (2019) A 16-yr Follow-up of the European randomized study of screening for prostate cancer. Eur Urol 76(1):43\u201351. https:\/\/doi.org\/10.1016\/j.eururo.2019.02.009Epub 2019 Feb 26. PMID: 30824296; PMCID: PMC7513694","journal-title":"Eur Urol"},{"issue":"4","key":"5606_CR7","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.eururo.2023.03.016","volume":"84","author":"II de Vos","year":"2023","unstructured":"de Vos II, Meertens A, Hogenhout R, Remmers S, Roobol MJ, ERSPC Rotterdam Study Group (2023) A detailed evaluation of the effect of prostate-specific Antigen-based screening on morbidity and mortality of prostate cancer: 21-year Follow-up results of the Rotterdam section of the European randomised study of screening for prostate cancer. Eur Urol 84(4):426\u2013434 Epub 2023 Apr 5. PMID: 37029074","journal-title":"Eur Urol"},{"issue":"4","key":"5606_CR8","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/s41391-020-0239-x","volume":"23","author":"TR McClintock","year":"2020","unstructured":"McClintock TR, Cone EB, Marchese M et al (2020) Prostate cancer management costs vary by disease stage at presentation. Prostate Cancer Prostatic Dis 23(4):564\u2013566. https:\/\/doi.org\/10.1038\/s41391-020-0239-xEpub 2020 May 14. PMID: 32409730","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"3","key":"5606_CR9","doi-asserted-by":"publisher","first-page":"e222246","DOI":"10.1001\/jamanetworkopen.2022.2246","volume":"5","author":"MM Desai","year":"2022","unstructured":"Desai MM, Cacciamani GE, Gill K et al (2022) Trends in incidence of metastatic prostate cancer in the US. JAMA Netw Open 5(3):e222246. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.2246PMID: 35285916; PMCID: PMC9907338","journal-title":"JAMA Netw Open"},{"issue":"2","key":"5606_CR10","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1097\/JU.0000000000001361","volume":"205","author":"CM de la Calle","year":"2021","unstructured":"de la Calle CM, Fasulo V, Cowan JE et al (2021) Clinical utility of 4Kscore\u00ae, exosomedx\u2122 and magnetic resonance imaging for the early detection of high grade prostate cancer. J Urol 205(2):452\u2013460. https:\/\/doi.org\/10.1097\/JU.0000000000001361","journal-title":"J Urol"},{"key":"5606_CR11","doi-asserted-by":"publisher","unstructured":"Vynckier P, Annemans L, Raes S et al (2024) Systematic review on the cost effectiveness of prostate cancer screening in Europe. Eur Urol Published Online May 23. https:\/\/doi.org\/10.1016\/j.eururo.2024.04.036","DOI":"10.1016\/j.eururo.2024.04.036"},{"issue":"8","key":"5606_CR12","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1515\/cclm-2022-0354","volume":"60","author":"L Agnello","year":"2022","unstructured":"Agnello L, Vidali M, Giglio RV et al (2022) Prostate health index (PHI) as a reliable biomarker for prostate cancer: a systematic review and meta-analysis. Clin Chem Lab Med 60(8):1261\u20131277 Published 2022 May 16. https:\/\/doi.org\/10.1515\/cclm-2022-0354","journal-title":"Clin Chem Lab Med"},{"key":"5606_CR13","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.3390\/ijms21041184","volume":"21","author":"M Ferro","year":"2020","unstructured":"Ferro M, De Cobelli O, Lucarelli G et al (2020) Beyond PSA: the role of prostate health index (phi). Int J Mol Sci 21:1184. https:\/\/doi.org\/10.3390\/ijms21041184","journal-title":"Int J Mol Sci"},{"key":"5606_CR14","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/oso\/9780198529446.001.0001","volume-title":"Methods for the economic evaluation of health care programmes","author":"MF Drummond","year":"2005","unstructured":"Drummond MF, Sculpher MJ, Torrance GW et al (2005) Methods for the economic evaluation of health care programmes. Oxford University Press, Oxford, p 404"},{"key":"5606_CR15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.urology.2019.06.011","volume":"133","author":"MD Gross","year":"2019","unstructured":"Gross MD, Alshak MN, Shoag JE et al (2019) Healthcare costs of Post-Prostate biopsy sepsis. Urology 133:11\u201315. https:\/\/doi.org\/10.1016\/j.urology.2019.06.011Epub 2019 Jun 21. PMID: 31229516","journal-title":"Urology"},{"key":"5606_CR16","doi-asserted-by":"publisher","first-page":"117270","DOI":"10.1016\/j.cca.2023.117270","volume":"542","author":"L Rius Bilbao","year":"2023","unstructured":"Rius Bilbao L, Valladares Gomez C, Aguirre Larracoechea U et al (2023) Do PHI and PHI density improve detection of clinically significant prostate cancer only in the PSA Gray zone? Clin Chim Acta 542:117270. https:\/\/doi.org\/10.1016\/j.cca.2023.117270","journal-title":"Clin Chim Acta"},{"issue":"10\u201311","key":"5606_CR17","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.clinbiochem.2010.04.062","volume":"43","author":"A Semjonow","year":"2010","unstructured":"Semjonow A, K\u00f6pke T, Eltze E, Pepping-Schefers B, B\u00fcrgel H, Darte C (2010) Pre-analytical in-vitro stability of [-2]proPSA in blood and serum. Clin Biochem 43(10\u201311):926\u2013928. https:\/\/doi.org\/10.1016\/j.clinbiochem.2010.04.062","journal-title":"Clin Biochem"},{"key":"5606_CR18","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.eururo.2013.01.011","volume":"63","author":"M Lazzeri","year":"2013","unstructured":"Lazzeri M, Haese A, de la Taille A et al (2013) Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2\u201310 Ng\/mL: a multicentric European study. Eur Urol 63:986\u2013994","journal-title":"Eur Urol"},{"key":"5606_CR19","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.juro.2014.10.121","volume":"193","author":"S Loeb","year":"2015","unstructured":"Loeb S, Sanda MG, Broyles DL et al (2015) The prostate health index (phi) selectively identifies clinically-significant prostate cancer. J Urol 193:1163\u20131169","journal-title":"J Urol"},{"key":"5606_CR20","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.eururo.2014.08.010","volume":"68","author":"T Nordstr\u00f6m","year":"2015","unstructured":"Nordstr\u00f6m T, Vickers A, Assel M et al (2015) Comparison between the four- Kallikrein panel and prostate health index for predicting prostate cancer. Eur Urol 68:139\u2013146","journal-title":"Eur Urol"},{"issue":"6","key":"5606_CR21","doi-asserted-by":"publisher","first-page":"691","DOI":"10.5858\/arpa.2021-0079-OA","volume":"146","author":"MM Garrido","year":"2022","unstructured":"Garrido MM, Marta JC, Bernardino RM et al (2022) The percentage of [-2]Pro-Prostate-Specific antigen and the prostate health index outperform prostate-Specific antigen and the percentage of free prostate- specific antigen in the detection of clinically significant prostate cancer and can be used as reflex tests. Arch Pathol Lab Med 146(6):691\u2013700","journal-title":"Arch Pathol Lab Med"},{"issue":"17","key":"5606_CR22","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1001\/jama.2024.3841","volume":"331","author":"A Auvinen","year":"2024","unstructured":"Auvinen A, Tammela TLJ, Mirtti T et al (2024) ProScreen trial investigators. Prostate cancer screening with PSA, Kallikrein panel, and MRI: the proscreen randomized trial. JAMA 331(17):1452\u20131459. https:\/\/doi.org\/10.1001\/jama.2024.3841PMID: 38581254; PMCID: PMC10999002","journal-title":"JAMA"},{"issue":"2","key":"5606_CR23","doi-asserted-by":"publisher","first-page":"e2354577","DOI":"10.1001\/jamanetworkopen.2023.54577","volume":"7","author":"T Nordstr\u00f6m","year":"2024","unstructured":"Nordstr\u00f6m T, Annerstedt M, Glaessgen A et al (2024) Repeated prostate cancer screening using prostate-Specific antigen testing and magnetic resonance imaging: A secondary analysis of the STHLM3-MRI randomized clinical trial. JAMA Netw Open 7(2):e2354577. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.54577PMID: 38324313; PMCID: PMC10851096","journal-title":"JAMA Netw Open"},{"issue":"4","key":"5606_CR24","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s00345-022-03947-y","volume":"41","author":"C W\u00fcrnschimmel","year":"2023","unstructured":"W\u00fcrnschimmel C, Chandrasekar T, Hahn L, Esen T, Shariat SF, Tilki D (2023) MRI as a screening tool for prostate cancer: current evidence and future challenges. World J Urol 41(4):921\u2013928. https:\/\/doi.org\/10.1007\/s00345-022-03947-yEpub 2022 Feb 28. PMID: 35226140; PMCID: PMC10160206","journal-title":"World J Urol"},{"issue":"4","key":"5606_CR25","doi-asserted-by":"publisher","first-page":"e070280","DOI":"10.1136\/bmjopen-2022-070280","volume":"13","author":"A Asif","year":"2023","unstructured":"Asif A, Nathan A, Ng A et al (2023) Comparing biparametric to multiparametric MRI in the diagnosis of clinically significant prostate cancer in biopsy-naive men (PRIME): a prospective, international, multicentre, non-inferiority within-patient, diagnostic yield trial protocol. BMJ Open 13(4):e070280. https:\/\/doi.org\/10.1136\/bmjopen-2022-070280PMID: 37019486; PMCID: PMC10083803","journal-title":"BMJ Open"},{"key":"5606_CR26","doi-asserted-by":"publisher","unstructured":"Van Calster B, McLernon DJ, van Smeden M, Wynants L, Steyerberg EW (2019) Topic Group \u2018Evaluating diagnostic tests and prediction models\u2019 of the STRATOS initiative. Calibration: the Achilles heel of predictive analytics. BMC Med. 17(1):230. Published 2019 Dec 16. https:\/\/doi.org\/10.1186\/s12916-019-1466-","DOI":"10.1186\/s12916-019-1466-"},{"key":"5606_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.euros.2021.11.002","volume":"36","author":"S Remmers","year":"2021","unstructured":"Remmers S, Kasivisvanathan V, Verbeek JFM, Moore CM, Roobol MJ, ERSPC Rotterdam Study Group PRECISION Investigators Group (2021) Reducing biopsies and magnetic resonance imaging scans during the diagnostic pathway of prostate cancer: applying the Rotterdam prostate cancer risk calculator to the PRECISION trial data. Eur Urol Open Sci 36:1\u20138 Published 2021 Dec 15. https:\/\/doi.org\/10.1016\/j.euros.2021.11.002","journal-title":"Eur Urol Open Sci"},{"issue":"5","key":"5606_CR28","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/bco2.146","volume":"3","author":"P Davik","year":"2022","unstructured":"Davik P, Remmers S, Elschot M, Roobol MJ, Bathen TF, Bertilsson H (2022) Reducing prostate biopsies and magnetic resonance imaging with prostate cancer risk stratification. BJUI Compass 3(5):344\u2013353 Published 2022 Apr 22. https:\/\/doi.org\/10.1002\/bco2.146","journal-title":"BJUI Compass"},{"issue":"5","key":"5606_CR29","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1111\/bju.13437","volume":"118","author":"RW Foley","year":"2016","unstructured":"Foley RW, Maweni RM, Gorman L et al (2016) European randomised study of screening for prostate cancer (ERSPC) risk calculators significantly outperform the prostate cancer prevention trial (PCPT) 2.0 in the prediction of prostate cancer: a multi-institutional study. BJU Int 118(5):706\u2013713. https:\/\/doi.org\/10.1111\/bju.13437","journal-title":"BJU Int"},{"issue":"1","key":"5606_CR30","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/bju.13676","volume":"120","author":"S Loeb","year":"2017","unstructured":"Loeb S, Shin SS, Broyles DL et al (2017) Prostate health index improves multivariable risk prediction of aggressive prostate cancer. BJU Int 120(1):61\u201368. https:\/\/doi.org\/10.1111\/bju.13676","journal-title":"BJU Int"},{"key":"5606_CR31","doi-asserted-by":"publisher","unstructured":"Nichol MB, Wu J, Huang J, Denham D, Frencher SK, Jacobsen SJ (2012) Cost-effectiveness of Prostate Health Index for prostate cancer detection. BJU Int. 110(3):353\u2009\u2013\u200962. https:\/\/doi.org\/10.1111\/j.1464-410X.2011.10751.x. Epub 2011 Nov 11. PMID: 22077934","DOI":"10.1111\/j.1464-410X.2011.10751.x"},{"key":"5606_CR32","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jval.2015.12.002","volume":"19","author":"EA Heijnsdijk","year":"2016","unstructured":"Heijnsdijk EA, Denham D, de Koning HJ (2016) The cost-effectiveness of prostate cancer detection with the use of prostate health index. Value Health 19:153\u2013157","journal-title":"Value Health"},{"issue":"6","key":"5606_CR33","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s10198-021-01414-w","volume":"23","author":"L Garc\u00eda-Moch\u00f3n","year":"2022","unstructured":"Garc\u00eda-Moch\u00f3n L, \u0160pac\u00edrov\u00e1 Z, Esp\u00edn J (2022) Costing methodologies in European economic evaluation guidelines: commonalities and divergences. Eur J Health Econ 23(6):979\u2013991. https:\/\/doi.org\/10.1007\/s10198-021-01414-wEpub 2021 Nov 26. PMID: 34825296","journal-title":"Eur J Health Econ"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05606-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-025-05606-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05606-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T22:02:50Z","timestamp":1767996170000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-025-05606-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5606"],"URL":"https:\/\/doi.org\/10.1007\/s00345-025-05606-4","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,20]]},"assertion":[{"value":"16 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"504"}}